<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02098486</url>
  </required_header>
  <id_info>
    <org_study_id>ERCPMOXIVSCEF</org_study_id>
    <nct_id>NCT02098486</nct_id>
  </id_info>
  <brief_title>Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP</brief_title>
  <official_title>Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and aims: The use of prophylactic antibiotics before endoscopic retrograde
      cholangiopancreatography (ERCP) is recommended by all major international
      gastroenterological societies, especially in the presence of an obstructed biliary system.
      Their use is intended to decrease or eliminate the incidence of complications following the
      procedure, namely cholangitis, cholecystitis, septicemia, and pancreatitis. However, there
      were a few reports concerning the dosage, duration and adopting antibiotics most suitable
      for this purpose. The aim of this prospective comparative study is to compare the occurrence
      rate of post-procedural complications, such as cholangitis, bacteremia and septicemia
      between intravenous moxifloxacin and ceftriaxone for the prophylactic use in patients with
      bile duct obstruction who will undergo therapeutic ERCP procedure.

      Methods: In this prospective study, a total of 160 patients (calculated by IBM SPSS Sample
      Power, version 3.0) with bile duct obstruction due to variable causes (bile duct stones,
      benign or malignant stricture, etc) will be enrolled and randomly allocated to intravenous
      moxifloxacin and ceftriaxone group, respectively (using simple randomization program).
      Intravenous moxifloxacin (400 mg/day, infused more than 60 min) or ceftriaxone (2 g/day,
      diluted in 40 cc of 5% dextrose water, infused more than 30 min) will be given 90 minutes
      before ERCP procedure, and will be given to a patient for more than 3 days if the patient
      develops symptoms and signs of cholangitis or septicemia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>cholangitis</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the occurrence rate of cholangitis between the intravenous moxifloxacin and ceftriaxone group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the occurrence rate of 30-day mortality between moxifloxacin and ceftriaxone treated group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cholangitis</condition>
  <arm_group>
    <arm_group_label>Ceftraxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous moxifloxacin (400 mg/day, infused more than 60 min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <arm_group_label>Ceftraxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with bile duct obstruction due to variable causes (bile duct stones, benign
             or malignant stricture, etc)

        Exclusion Criteria:

          -  pregnancy

          -  hypersensitivity to moxifloxacin and/or ceftriaxone

          -  previous antibiotic exposure or theophyllin derivatives medication within 14 days of
             admission

          -  previous history of epilepsy

          -  previous history of endocarditis of valvular heart disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Joo Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sungkyunkwan University Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Joo Kim, MD</last_name>
    <phone>+82-2-2001-8556</phone>
    <email>ringer2003@gmail.com</email>
  </overall_contact>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Hong Joo Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Bile duct obstruction</keyword>
  <keyword>Cholangitis</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Ceftriaxone</keyword>
  <keyword>Sepsis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
